BMY's CELMoD Phase III Win Highlights Pipeline Strength, But Core Transition Risks Loom

What happened

Bristol Myers Squibb reported positive phase III SUCCESSOR-2 data for mezigdomide in relapsed multiple myeloma, boosting its CELMoD program as part of the Growth Portfolio. This news arrives amid a critical portfolio transition where BMY's near-term thesis, per the DeepValue report, hinges on Eliquis delivering +10-15% growth in 2026 while defending gross margins at 69-70% despite IRA and Medicaid changes. The CELMoD success adds momentum to the Growth Portfolio, which grew 17% in FY25 and is essential to offset legacy declines like Revlimid's accelerated erosion post-January 31, 2026. However, filings reveal policy-fragile economics for Eliquis, including a Medicaid free-supply agreement effective January 1, 2026, which could pressure margins even if volume targets are met. Thus, while this pipeline win is encouraging, it does not mitigate the immediate need for observable proof on Eliquis performance and margin stability in upcoming quarters.

Implication

The CELMoD success reinforces BMY's pipeline potential in oncology, supporting the Growth Portfolio's role in offsetting legacy declines, but the investment thesis remains anchored to Eliquis bridging the transition with stable margins. If Eliquis growth in 2026 is achieved through concessions, gross margin could break below the guided 69-70%, triggering a bear-case revaluation toward $52 per share. Upcoming Q1-Q2 2026 results will provide clear evidence on whether management's guidance holds, with margin stability being a key monitorable to avoid downside from policy-driven pricing pressures. Therefore, while pipeline progress is positive, it does not reduce the necessity for confirmation on financial metrics before considering an entry. Investors should prioritize monitoring Eliquis sales trends and margin prints over pipeline news until the transition risks are resolved.

Thesis delta

The positive phase III results for mezigdomide do not shift the core investment thesis, which is predicated on Eliquis sustaining growth and margins during BMY's portfolio transition. However, it slightly enhances the bull case by demonstrating progress in the CELMoD program, a component of the Growth Portfolio that needs to offset legacy erosion. Overall, the wait rating and conviction remain unchanged, as the critical near-term financial risks around Eliquis and gross margins are unaffected by this pipeline development.